Skip to content
DataLookout
Menu

NCT07873645

Study of UBT37034 Injection

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 2026 to Oct 15, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of Adverse Events (AEs)
Timeframe: Baseline to Week23
Change from baseline in physical examinations
Timeframe: Baseline to Week 23
Change from baseline in body temperature
Timeframe: Baseline to Week 23
Change from baseline in pulse rate
Timeframe: Baseline to Week 23
Change from baseline in blood pressure
Timeframe: Baseline to Week 23
Change from baseline in ECG QTcF interval
Timeframe: Baseline to Week 23
Change from baseline in ECG RR interval
Timeframe: Baseline to Week 23
Change from baseline in ECG heart rate
Timeframe: Baseline to Week 23
Change from baseline in PHQ-9 total score
Timeframe: Baseline to Week 23
Change from baseline in C-SSRS score
Timeframe: Baseline to Week 23

Secondary (12)

Cmax
Tmax
AUC0-t
AUC0-τ
Change from baseline in body weight
Show 7 moreShow less
Change from baseline in Body Mass Index (BMI)
Change from baseline in Waist Circumference (WC)
Change from baseline in Waist-to-Hip Ratio (WHR)
Change from baseline in Glycated Hemoglobin (HbA1c)
Positive rate of anti-UBT37034 antibodies
Antibody titer levels in anti-UBT37034 antibody-positive participants
Positive rate of neutralizing antibodies (if applicable)

Arms and interventions

UBT37034 Dose 1Experimental

Participants will receive UBT37034 subcutaneously (SC).

UBT37034 Dose 2Experimental

Participants will receive UBT37034 subcutaneously (SC).

UBT37034 Dose 3Experimental

Participants will receive UBT37034 subcutaneously (SC).

UBT37034 Dose 4Experimental

Participants will receive UBT37034 subcutaneously (SC).

PlaceboPlacebo comparator

Participants will receive placebo.

Drugs: UBT37034, Placebo

Sites

1 site in 1 country

  • The Third Xiangya Hospital of Central South UniversityChangsha, Hunan, China